A groundbreaking study led by researchers at Rutgers Health has unveiled pivotal insights into the genetic architecture underlying substance use disorders (SUDs). This extensive genetic investigation, incorporating data from over 2.2 million individuals, elucidates how addiction risk is predominantly influenced by genes that govern broad neurological functions rather than those specific to individual substances. The findings, published in Nature Mental Health, reshape our understanding of addiction’s genetic basis and open new avenues for targeted prevention and therapeutic intervention.
Traditional genetic studies on substance use disorders have often compartmentalized each addiction type independently, focusing on genes linked explicitly to alcohol, tobacco, cannabis, or opioids. However, this new research challenges that siloed approach by revealing that the majority of genetic vulnerability transcends specific substances and instead converges on a broad genomic pathway related to behavioral disinhibition. This pathway encompasses neural circuits managing reward processing, impulse control, and risk-taking behaviors, underlining the brain’s wiring as a critical determinant in addiction susceptibility.
Behavioral disinhibition, characterized by traits such as impulsivity, attention-deficit/hyperactivity disorder (ADHD), and conduct problems, manifests as difficulty regulating impulses and decision-making. The Rutgers team demonstrated that genetic variants influencing these externalizing behaviors substantially overlap with those implicated in multiple substance use disorders, suggesting a unified biological substrate. This discovery highlights the importance of viewing addiction through a broader psychological and neurobiological lens rather than isolating individual drugs.
Alongside this broad externalizing genetic pathway, the study identified substance-specific genetic influences. These genes impact processes unique to particular substances, such as alcohol metabolism enzymes or nicotinic acetylcholine receptors involved in tobacco use. While these substance-specific genes provide nuanced insight into addiction mechanics for distinct drugs, their role appears less prominent compared to the overarching influence of genes regulating neural control and reward networks.
Led by Holly Poore, a faculty instructor in psychiatry, and senior author Danielle Dick from the Rutgers Addiction Research Center within the Rutgers Brain Health Institute, the research utilized advanced multivariate genomic analyses. By integrating genetic data across multiple cohorts and disorders, the team circumvented prior limitations of single-disorder genome-wide association studies (GWAS), enhancing the statistical power to detect shared and unique genetic factors contributing to addiction risk.
The methodology incorporated genetic markers not only for substance dependence but also for associated externalizing traits like ADHD and risk-taking propensity. This integrative approach enhanced the detection of hundreds of genetic variants involved in a wide externalizing liability, offering a more comprehensive genetic map of addiction vulnerability. It further distinguished these from variants exclusive to particular substances, thereby delineating two parallel genetic pathways influencing addiction onset and progression.
Importantly, the research team constructed polygenic risk scores from their genomic findings. These scores condense thousands of genetic variants into composite indices, representing an individual’s inherited liability to addiction. Broad externalizing polygenic scores were found to robustly predict the risk across multiple substance use disorders, whereas substance-specific scores provided refined predictions for vulnerability to particular drugs. This dual-layered genetic risk profiling holds promise for precision medicine applications in addiction.
Danielle Dick emphasized that genetic predisposition is not deterministic but facilitates identification of individuals at greater risk for addictive behaviors. These findings pave the way for early interventions and personalized prevention strategies tailored to genetic susceptibility profiles. Moreover, the delineation of shared versus substance-specific genetic influences could inform the development of novel pharmacological treatments targeting critical neural pathways underpinning behavioral disinhibition.
Beyond genetic associations, the study extended to network and drug-target analyses, revealing overlaps between genes implicated in broad externalizing pathways and those involved in other psychiatric conditions. This intersection underlines a shared biological architecture of addiction with mental health disorders, suggesting that therapeutics modulating these pathways may have cross-disorder efficacy. Such insights foster integrative approaches to treating co-morbid psychiatric and substance use conditions.
Despite its broad scale and impactful revelations, the study’s analyses were confined to individuals of European ancestry due to existing data availability. This limitation underscores a pressing need for more diverse genomic datasets to ensure that findings and consequent interventions equitably benefit global populations. Expanding research across diverse ancestral groups remains critical to unlocking universal and population-specific aspects of addiction genetics.
Holly Poore highlighted the necessity of moving beyond investigating single genes or substances in isolation. This comprehensive genetic perspective captures the complexity of addiction as a multifaceted brain disorder shaped by intertwined gene networks. Understanding these intricacies not only deepens scientific knowledge but also equips clinicians and policymakers with better tools to combat the burden of addiction worldwide.
The international collaboration, involving prestigious institutions such as SUNY Downstate, University of California San Diego, Massachusetts General Hospital, Harvard Medical School, Washington University in St. Louis, Emory University, the University of Texas at Austin, and Vanderbilt University Medical Center, reflects the multifaceted effort required to tackle the complexities of addiction genomics. Contributions from extensive genetic consortia, including the Collaborative Study on the Genetics of Alcoholism, were instrumental in aggregating the vast genetic data necessary for such comprehensive analyses.
This seminal work heralds a paradigm shift in addiction genetics by revealing the preeminence of broad neurobehavioral pathways over substance-specific genetic mechanisms. As research continues to evolve, these insights will be integral to developing sophisticated genetic risk models, enabling targeted prevention, and optimizing individualized treatment strategies. Ultimately, such advances bring hope for more effective combat against the global health challenge posed by substance use disorders.
Subject of Research: Cells
Article Title: Multivariate genetic analyses of 2.2 million individuals reveal broad and substance-specific pathways of addiction risk
News Publication Date: 20-Mar-2026
Web References:
http://dx.doi.org/10.1038/s44220-026-00608-6
References:
Poore H, Dick D, et al. (2026). Multivariate genetic analyses of 2.2 million individuals reveal broad and substance-specific pathways of addiction risk. Nature Mental Health. DOI: 10.1038/s44220-026-00608-6
Keywords: Addiction, Genetic analysis, Substance use disorder, Behavioral disinhibition, Polygenic risk scores, Neurogenetics, Psychiatric genetics
Tags: ADHD and addiction riskbehavioral disinhibition and substance use disordersbroad genetic factors in addictiongenetic basis of addiction riskgenetic overlap in substance use disordersgenetic research on substance use disordersimpulse control genes and addictionimpulsivity and addiction vulnerabilityneurological pathways in addictionreward processing and addiction geneticsRutgers Health addiction studytargeted prevention for addiction
